[Multimodal therapy of dyslipidemia].

Abstract

In the multifactorial process of atherogenesis not only increased LDL-cholesterol but also decreased HDL-cholesterol and raised triglycerides correlate closely to cardiovascular events. Multiple studies have demonstrated a high prevalence of dyslipidemia and the metabolic syndrome in Germany.Statins remain first-line therapy for the treatment of dyslipidemia. However, despite therapy a relevant cardiovascular risk remains. Therefore, it is important to also aim for an adequate treatment of hypertriglyceridemia and also to raise HDL-levels. Many combination therapies have been shown to be effective in treating dyslipidemia. Adding Omega-3-fatty acids, nicotinic acid/laropiprant or a fibrate to statin monotherapy provide additional beneficial lipid-modifying effects for combined dyslipidemia. In the future a recommendation for the treatment of mixed hyperlipoproteinemia with decreased HDL, raised triglycerides and LDL-cholesterol shall have to be added to our guidelines.

• Authors: Annett Stahn, Markolf Hanefeld
• Journal: Clinical research in cardiology supplements (Clin Res Cardiol Suppl) Vol. 6 Pg. 10-6 (May 2011) ISSN: 1861-0714 [Electronic] Germany
• Vernacular Title: Multimodale Therapie von Fettstoffwechselstörungen.
• PMID: 22528173 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Biomarkers
• Fatty Acids, Omega-3
• Fibric Acids
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Hypolipidemic Agents
• Indoles
• Lipids
• MK-0524
• Niacin

Topics

• Animals
• Biomarkers (blood)
• Drug Therapy, Combination
• Dyslipidemias (blood, diagnosis, drug therapy, epidemiology)
• Fatty Acids, Omega-3 (therapeutic use)
• Fibric Acids (therapeutic use)
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Hypolipidemic Agents (adverse effects, therapeutic use)
• Indoles (therapeutic use)
• Lipids (blood)
• Niacin (therapeutic use)
• Practice Guidelines as Topic
• Treatment Outcome